Biopharma | June 26, 2026
Moderna outlines aggressive multi-modal growth strategy
The company emphasized that its mRNA system is built on three pillars—mRNA science, delivery science, and manufacturing processes
The company emphasized that its mRNA system is built on three pillars—mRNA science, delivery science, and manufacturing processes
Company secures 7th position nationwide in India's Great Mid-size Workplaces 2026, reinforcing its people-first culture as it marks 75 years of excellence
The company plans to use this funding to boost AI capabilities, expand vernacular content ecosystem, accelerate product development, and scale user acquisition across Tier 2 and Tier 3 markets
This makes the company among few in India to offer fully integrated, end-to-end ADC drug substance development and manufacturing, encompassing payload synthesis, linker development and manufacturing
Innovative start-up award recognizes LIBERTY as a highly innovative, ground-breaking product with potentially wide range and/or substantial benefit
The collaboration comes at a time when access to high-quality fertility treatment remains uneven, despite rapid market expansion
Bengaluru-based startup recognised for building autonomous AI agents for pharmaceutical and medtech commercial operations, joins select cohort of 40 startups in India-focused accelerator programme
The company reported consolidated revenue of Rs. 172.9 crore and EBITDA of Rs 25.9 crore in FY26
Clearing 19 biologics for Europe market
The incubator anchored at the company's global headquarters in Raleighla launches alongside an inaugural partnership with Cape Fear BioCapital, a Durham-based seed-stage venture capital firm
Subscribe To Our Newsletter & Stay Updated
